osteolabs GmbH, an innovative diagnostic company applying its proprietary CIM (Calcium isotope marker) technology for the early detection of Calcium-related metabolic bone diseases affecting over 1 billion patients worldwide, announced today the publication of real-world evidence data from close to 3,000 OsteoTest patient samples in the prestigious journal Bone. 

The publication, accessible online (DOI: https://doi.org/10.1016/j.bone.2024.117210) marks the first report on the real-world application of CIM in the serum and urine of 2,960 patient samples in total. This study was conducted in collaboration with renowned colleagues at GEOMAR (Helmholtz-Center for Ocean Research Kiel, Germany), the University Hospital Schleswig-Holstein (UKSH, Kiel, Germany), and the UCL Great Ormond Street Hospital (London, United Kingdom). The data demonstrate a strong correlation between CIM and various metabolic diseases affecting musculoskeletal metabolism. Furthermore, the results align in full accordance with earlier clinical validation data and the established CIM threshold values for Bone Calcium Balance (BCaB).(1)

“We are very excited about the results from this collaborative effort that have now culminated in a publication in Bone, “ said Prof. Anton Eisenhauer who is a key inventor of the CIM technology and osteolabs´ Chief Scientific Officer. “This larger subset of routine clinical samples fully supports the potential for OsteoTest to qualify as a new universal diagnostic method for early osteoporosis risk assessment and therapeutic control.”